Published in Am J Psychiatry on July 01, 1999
Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry (2003) 0.88
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry (1997) 2.65
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry (1990) 2.12
Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol (1991) 1.46
Interaction between caffeine and clozapine. J Clin Psychopharmacol (1994) 1.39
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. Am J Psychiatry (1984) 1.37
Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A (1994) 1.30
Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol (2000) 1.27
A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol (1994) 1.19
Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry (1978) 1.19
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry (1985) 1.17
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry (1980) 1.09
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry (1995) 1.08
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci (1995) 1.07
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. Can Med Assoc J (1978) 1.07
Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatry (1979) 1.07
Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology (Berl) (1982) 1.05
A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl (1990) 1.05
Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis (1982) 1.04
Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther (1994) 1.02
Schizophreniform psychosis associated with chronic industrial toluene exposure: case report. J Clin Psychiatry (1985) 1.00
Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol (1999) 0.99
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry (1993) 0.99
Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry (1998) 0.97
Schizophrenia as dopamine-deficiency disease. Lancet (1978) 0.96
Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol (2000) 0.93
Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. Schizophr Res (2006) 0.92
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand (1979) 0.91
The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry (1995) 0.90
Effects of five insecticides used in apple orchards on Hyaliodes vitripennis (Say) (Hemiptera: Miridae). J Environ Sci Health B (2000) 0.90
A guide to benzodiazepine selection. Part I: Pharmacological aspects. Can J Psychiatry (1990) 0.89
Early onset of tardive dyskinesia: case report. Am J Psychiatry (1979) 0.89
Cutaneous vasculitis induced by paroxetine. Am J Psychiatry (2001) 0.89
Phenothiazine-induced ECG abnormalities: effect of a glucose load. Arch Gen Psychiatry (1977) 0.88
A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol (1995) 0.88
Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol (1990) 0.87
Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry (1979) 0.86
New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.86
Factors related to tardive dyskinesia. Am J Psychiatry (1979) 0.84
A case of mania associated with tomoxetine. Am J Psychiatry (1985) 0.84
Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry (1989) 0.83
A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry (1985) 0.83
Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? Int Clin Psychopharmacol (2002) 0.83
Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol (1987) 0.83
Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry (1988) 0.82
A five year follow-up study of tardive dyskinesia. Psychopharmacol Bull (1986) 0.82
Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry (1983) 0.81
Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam. Psychopharmacol Bull (1985) 0.81
Olanzapine-induced somnambulism. Am J Psychiatry (2001) 0.81
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. Am J Med Genet (1994) 0.80
Articulatory impairment associated with tardive dyskinesia. J Nerv Ment Dis (1990) 0.80
Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol (1994) 0.80
Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. J Clin Psychopharmacol (1998) 0.80
[Iatrogenic psychiatric-like symptoms recognition]. Encephale (2010) 0.80
Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. Br J Clin Pharmacol (1987) 0.80
A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry (1983) 0.80
Didanosine-induced mania in HIV infection. Am J Psychiatry (1994) 0.79
Antimanic effect of clonazepam. Biol Psychiatry (1983) 0.79
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry (1982) 0.79
Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.79
Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull (1986) 0.79
Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol (1983) 0.79
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci (1997) 0.79
Lithium and regression of oat-cell carcinoma. Can Med Assoc J (1981) 0.79
Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J (1982) 0.78
Antipanic effect of clonazepam. Am J Psychiatry (1984) 0.78
Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull (1987) 0.78
A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. Int Pharmacopsychiatry (1977) 0.78
Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology (Berl) (1982) 0.78
Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand (1990) 0.78
Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant. Int J Neuropsychopharmacol (2005) 0.78
A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol (1986) 0.78
Diphenhydramine (Unisom), a central anticholinergic and antihistaminic: abuse with massive ingestion in a patient with schizophrenia. Can J Psychiatry (2000) 0.77
Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand (1981) 0.77
Treatment of antidepressant-induced sexual side effects. J Sex Marital Ther (1996) 0.77
A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry (1996) 0.77
An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol (1986) 0.77
An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) (1984) 0.77
An early Phase II clinical trial with followup of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull (1985) 0.77
Clozapine in the treatment of newly admitted schizophrenic patients. A pilot study. J Clin Pharmacol (1976) 0.76
No crossover of hypersensitivity between zimelidine and fluoxetine. Can Med Assoc J (1984) 0.76
Tryptophan in the treatment of depression. Adv Exp Med Biol (1981) 0.76
Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand (1986) 0.76
Evidence of brain dopamine deficiency in schizophrenia. Can J Psychiatry (1979) 0.76
Tryptophan-nicotinamide combination in depression. Lancet (1977) 0.76
Antiobsessive effect of fluoxetine. Am J Psychiatry (1985) 0.76
Estrogen-progesterone combination: another mood stabilizer? Am J Psychiatry (1987) 0.76
Antimanic effects of clonazepam. Psychosomatics (1985) 0.76
Bromazepam and diazepam in generalized anxiety: a placebo-controlled study of efficacy and withdrawal. Psychopharmacol Bull (1984) 0.76
Absence of orthostatic hypotension in depressed patients treated with bupropion. Prog Neuropsychopharmacol (1981) 0.76
Hypomania induced by sertraline, a new serotonin reuptake inhibitor. Am J Psychiatry (1987) 0.76
Remoxipride in schizophrenia: effects on plasma prolactin. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.76
Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry (1986) 0.76
Bromazepam, another high-potency benzodiazepine, for panic attacks. Am J Psychiatry (1984) 0.76
Tryptophan dosage critical for its antidepressant effect. Br Med J (1978) 0.76
Death attributed to ventricular arrhythmia. Can Med Assoc J (1979) 0.75
Pimozide in the treatment of chronic schizophrenic patients. Curr Ther Res Clin Exp (1970) 0.75